CoreAge Rx vs KERNX Health
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and KERNX Health head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 73 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
That doesn't make KERNX Health a bad call — it's best for readers tracking what a program will cost at dose three, not just at sign-up. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | KERNX Health | |
|---|---|---|
| Brief Score | 94/100 (A) | 73/100 (C) |
| Semaglutide | $99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published | From $129/mo (compounded, plus a one-time consultation fee) |
| Tirzepatide | $149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published | From $229/mo (compounded, plus a one-time consultation fee) |
| Coverage | US only; restrictions by state, confirmed at intake | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.
KERNX Health: Re-read 30 August 2026 after the company disputed our first entry. The published line now reads From $129/mo for semaglutide and From $229/mo for tirzepatide, both dose-laddered. Our 30 July reading recorded $199 for tirzepatide, which was the top SEMAGLUTIDE rung recorded against the wrong molecule, so treat this as a corrected first reading rather than a price movement.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.